Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Journal
Affiliation country
Publication year range
1.
Blood ; 118(9): 2520-9, 2011 Sep 01.
Article in English | MEDLINE | ID: mdl-21757617

ABSTRACT

Human immunodeficiency virus (HIV) infection is characterized by a progressive loss of memory CD4(+) T cells in multiple tissues, especially at mucosal surfaces where most of these cells reside. Although antiretroviral therapy (ART) suppresses viral replication and promotes the recovery of peripheral CD4(+) T cells, HIV-infected patients fail to fully reconstitute the CD4(+) T-cell pool at mucosal sites. IL-15 has been shown to preferentially expand memory-phenotype T cells and promote their migration to nonlymphoid tissues. Here we examined IL-15 treatment in combination with highly active ART in chronically SIV-infected rhesus macaques and found that IL-15 delayed viral suppression and failed to enhance ART-induced total and antigen-specific CD4(+) T-cell reconstitution at mucosal and lymphoid sites. IL-15 was able to induce the transient proliferation of SIV-specific, CMV-specific, and total memory CD8(+) T cells, but not of SIV-specific or total CD4(+) T cells. Moreover, upon treatment interruption, macaques receiving combined IL-15+ART lost CD4(+) T cells faster than those receiving ART alone. These results suggest that the combination of IL-15 with highly active ART is not more efficient than ART alone in promoting CD4(+) T-cell recovery in HIV-infected individuals and may accelerate CD4+ T-cell loss after treatment interruption.


Subject(s)
Adenine/analogs & derivatives , Anti-Retroviral Agents/therapeutic use , CD4-Positive T-Lymphocytes/drug effects , Deoxycytidine/analogs & derivatives , Immunologic Factors/therapeutic use , Interleukin-15/therapeutic use , Organophosphonates/therapeutic use , Pyrrolidinones/therapeutic use , Simian Acquired Immunodeficiency Syndrome/immunology , Adaptive Immunity/drug effects , Adenine/administration & dosage , Adenine/pharmacology , Adenine/therapeutic use , Animals , Anti-Retroviral Agents/administration & dosage , Anti-Retroviral Agents/pharmacology , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , Deoxycytidine/administration & dosage , Deoxycytidine/pharmacology , Deoxycytidine/therapeutic use , Drug Evaluation, Preclinical , Drug Therapy, Combination , Emtricitabine , Immunity, Mucosal/drug effects , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Immunologic Factors/pharmacology , Immunotherapy , Interleukin-15/administration & dosage , Interleukin-15/adverse effects , Interleukin-15/pharmacology , Lymphocyte Activation , Lymphoid Tissue/immunology , Lymphoid Tissue/pathology , Macaca mulatta , Mucous Membrane/immunology , Mucous Membrane/pathology , Organophosphonates/administration & dosage , Organophosphonates/pharmacology , Pyrrolidinones/administration & dosage , Pyrrolidinones/pharmacology , Raltegravir Potassium , Random Allocation , Tenofovir , Treatment Failure , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL